Sept. 18, 2025
| Today’s news and insights for biopharma leaders
Roche’s CEO claimed 89bio’s drug, which is in late-stage testing, has the potential to show “best-in-disease efficacy” for many people with the condition.
|
The purchase gives Biogen full access to an implantable device that could help patients avoid the repeat lumbar punctures required for drugs like Spinraza.
|
T.Rx Capital was co-founded by Michael Langer, former Pear Therapeutics CEO Corey McMann and Eli Lilly veteran Kwesi Frimpong-Boateng, and raised just shy of $80 million for its first fund.
|
Smarter cold chain design starts with thermal modeling—learn best practices here.
|
Susan Monarez told Senators at a hearing Wednesday that Robert F. Kennedy Jr. pushed her out for refusing to rubber-stamp changes.
|
UPDATED
The remade ACIP panel is set to vote today on recommendations for use of vaccines for measles and hepatitis B. They’ll meet again tomorrow to discuss COVID shots.
|
From Our Library
Playbook
Custom content for PharmaForceIQ
|
Trendline
Supported by EVERSANA
|
Trendline
Supported by 10x Genomics
|
Trendline
Supported by ELEGEN
|
| 
